Extrapulmonary Comorbidities Associated with Chronic Obstructive Pulmonary Disease: A Review

被引:5
作者
Xiang, Yurong [1 ]
Luo, Xiaobin [2 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Sch Med & Life Sci, Chengdu 610000, Sichuan, Peoples R China
[2] Suining Cent Hosp, Dept Resp & Crit Care Med, Suining 629000, Sichuan, Peoples R China
来源
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2024年 / 19卷
关键词
chronic obstructive pulmonary disease; comorbidity; risk factors; therapeutics; GASTROESOPHAGEAL-REFLUX DISEASE; CARDIOVASCULAR-DISEASE; LUNG-FUNCTION; SYSTEMIC INFLAMMATION; ADVERSE OUTCOMES; CLINICAL IMPACT; STATIN USE; COPD; ANEMIA; EXACERBATIONS;
D O I
10.2147/COPD.S447739
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Most patients with chronic obstructive pulmonary disease (COPD) suffer from at least one additional, clinically relevant chronic disease. To a degree, the high global prevalence and mortality rate of COPD is closely related to its extrapulmonary effects. Moreover, the various of comorbidities of COPD and itself interact with each other, resulting in diverse clinical manifestations and individual differences, and thus further influencing the prognosis as well as healthcare burden of COPD patients. This is closely related to the common risk factors of chronic diseases (aging, smoking, inactivity, etc.). Additionally, some pathophysiological mechanisms caused by COPD, including the systemic inflammatory response, hypoxia, oxidative stress, and others, also have an impact on other systems. But comprehensive management and medical interventions have not yet been established. The clinicians should improve their knowledge and skills in diagnosing as well as treating the comorbidities of COPD, and then aim to develop more individualized, efficient diagnostic and therapeutic strategies for different patients to achieve greater clinical benefits. In this article, we will review the risk factors, mechanisms, and treatment strategies for extrapulmonary comorbidities in chronic obstructive pulmonary disease, including cardiovascular diseases, diabetes, anemia, osteoporosis, emotional disorders, and gastroesophageal reflux disease.
引用
收藏
页码:567 / 578
页数:12
相关论文
共 139 条
  • [1] A Longitudinal Cohort Study of Aspirin Use and Progression of Emphysema-like Lung Characteristics on CT Imaging The MESA Lung Study
    Aaron, Carrie P.
    Schwartz, Joseph E.
    Hoffman, Eric A.
    Angelini, Elsa
    Austin, John H. M.
    Cushman, Mary
    Jacobs, David R., Jr.
    Kaufman, Joel D.
    Laine, Andrew
    Smith, Lewis J.
    Yang, Jie
    Watson, Karol E.
    Tracy, Russell P.
    Barr, R. Graham
    [J]. CHEST, 2018, 154 (01) : 41 - 50
  • [2] Abbafati C, 2020, LANCET, V396, P1204
  • [3] Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
    Agusti, Alvar
    Celli, Bartolome R.
    Criner, Gerard J.
    Halpin, David
    Anzueto, Antonio
    Barnes, Peter
    Bourbeau, Jean
    Han, MeiLan K.
    Martinez, Fernando J.
    de Oca, Maria Montes
    Mortimer, Kevin
    Papi, Alberto
    Pavord, Ian
    Roche, Nicolas
    Salvi, Sundeep
    Sin, Don D.
    Singh, Dave
    Stockley, Robert
    Varela, M. Victorina Lopez
    Wedzicha, Jadwiga A.
    Vogelmeier, Claus F.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207 (07) : 819 - 837
  • [4] Concomitant Medication Use and New-Onset Diabetes Among Medicaid Beneficiaries with Chronic Obstructive Pulmonary Disease
    Ajmera, Mayank
    Shen, Chan
    Sambamoorthi, Usha
    [J]. POPULATION HEALTH MANAGEMENT, 2017, 20 (03) : 224 - 232
  • [5] Bisphosphonates for steroid-induced osteoporosis
    Allen, Claire S.
    Yeung, James H. S.
    Vandermeer, Ben
    Homik, Joanne
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (10):
  • [6] Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023)
    Almutairi, Shriefa
    Kalloush, Hanin Moh'd
    Manoon, Nour A.
    Bardaweel, Sanaa K.
    [J]. MOLECULES, 2023, 28 (14):
  • [7] New therapeutic targets for osteoporosis
    Anagnostis, Panagiotis
    Gkekas, Nifon K.
    Potoupnis, Michael
    Kenanidis, Eustathios
    Tsiridis, Eleftherios
    Goulis, Dimitrios G.
    [J]. MATURITAS, 2019, 120 : 1 - 6
  • [8] Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
    Andell, Pontus
    James, Stefan K.
    Cannon, Christopher P.
    Cyr, Derek D.
    Himmelmann, Anders
    Husted, Steen
    Keltai, Matyas
    Koul, Sasha
    Santoso, Anwar
    Steg, Gabriel
    Storey, Robert F.
    Wallentin, Lars
    Erlinge, David
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (10):
  • [9] COPD and Cardiovascular Disease
    Andre, S.
    Conde, B.
    Fragoso, E.
    Boleo-Tome, J. P.
    Areias, V.
    Cardoso, J.
    [J]. PULMONOLOGY, 2019, 25 (03): : 168 - 176
  • [10] Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong
    Au, Philip C. M.
    Tan, Kathryn C. B.
    Lam, David C. L.
    Cheung, Bernard M. Y.
    Wong, Ian C. K.
    Kwok, Wang Chun
    Sing, Chor-Wing
    Cheung, Ching-Lung
    [J]. JAMA NETWORK OPEN, 2023, 6 (01) : e2251177